Dimensional Fund Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$62M Buy
1,292,688
+41,840
+3% +$1.8M 0.01% 1469
2026
Q1
$46M Sell
1,250,848
-75,210
-6% -$3.56M 0.01% 1547
2025
Q4
$67.5M Sell
1,326,058
-12,589
-0.9% -$644K 0.01% 1342
2025
Q3
$74.3M Sell
1,338,647
-135,375
-9% -$7.92M 0.02% 1283
2025
Q2
$102M Sell
1,474,022
-5,600
-0.4% -$381K 0.02% 994
2025
Q1
$103M Sell
1,479,622
-4,147
-0.3% -$343K 0.03% 953
2024
Q4
$128M Sell
1,483,769
-159,635
-10% -$17.3M 0.03% 826
2024
Q3
$196M Buy
1,643,404
+23,665
+1% +$3.16M 0.05% 498
2024
Q2
$231M Sell
1,619,739
-128,604
-7% -$17M 0.06% 373
2024
Q1
$224M Sell
1,748,343
-26,456
-1% -$3.15M 0.06% 378
2023
Q4
$184M Sell
1,774,799
-3,535
-0.2% -$350K 0.05% 455
2023
Q3
$162M Buy
1,778,334
+45,188
+3% +$3.98M 0.05% 450
2023
Q2
$140M Buy
1,733,146
+44,618
+3% +$3.64M 0.04% 557
2023
Q1
$134M Buy
1,688,528
+9,584
+0.6% +$680K 0.05% 572
2022
Q4
$114K Buy
1,678,944
+109,744
+7% +$6.43M 0.03% 687
2022
Q3
$78.2M Buy
1,569,200
+43,958
+3% +$2.35M 0.03% 882
2022
Q2
$85M Buy
1,525,242
+46,072
+3% +$2.56M 0.03% 857
2022
Q1
$82.1M Buy
1,479,170
+13,806
+0.9% +$709K 0.03% 993
2021
Q4
$82.1M Buy
1,465,364
+34,356
+2% +$1.86M 0.02% 1043
2021
Q3
$68.7M Buy
1,431,008
+950
+0.1% +$45.9K 0.02% 1146
2021
Q2
$59.9M Sell
1,430,058
-39,072
-3% -$1.51M 0.02% 1288
2021
Q1
$49.5M Sell
1,469,130
-16,228
-1% -$578K 0.02% 1450
2020
Q4
$51.9M Buy
1,485,358
+644
+0% +$22.3K 0.02% 1335
2020
Q3
$51.5M Sell
1,484,714
-8,990
-0.6% -$300K 0.02% 1177
2020
Q2
$48.9M Hold
1,493,704
0.02% 1220
2020
Q1
$45M Sell
1,493,704
-1,818
-0.1% -$54.1K 0.02% 1106
2019
Q4
$43.3M Hold
1,495,522
0.02% 1552
2019
Q3
$38.7M Sell
1,495,522
-900
-0.1% -$22.8K 0.02% 1603
2019
Q2
$38.2M Buy
1,496,422
+5,136
+0.3% +$127K 0.01% 1650
2019
Q1
$39M Sell
1,491,286
-19,610
-1% -$482K 0.02% 1630
2018
Q4
$34.8M Sell
1,510,896
-102
-0% -$2.27K 0.02% 1606
2018
Q3
$35.6M Buy
1,510,998
+1,998
+0.1% +$48.8K 0.01% 1763
2018
Q2
$34.8M Hold
1,509,000
0.01% 1762
2018
Q1
$37.2M Hold
1,509,000
0.02% 1651
2017
Q4
$40.5M Buy
1,509,000
+3,492
+0.2% +$88.8K 0.02% 1571
2017
Q3
$36.2M Hold
1,505,508
0.02% 1619
2017
Q2
$32.3M Sell
1,505,508
-8,436
-0.6% -$170K 0.01% 1681
2017
Q1
$25.9M Sell
1,513,944
-2,016
-0.1% -$35.1K 0.01% 1826
2016
Q4
$27.2M Sell
1,515,960
-12,672
-0.8% -$230K 0.01% 1741
2016
Q3
$31.8M Sell
1,528,632
-66,606
-4% -$1.65M 0.02% 1511
2016
Q2
$42.9M Buy
1,595,238
+5,540
+0.3% +$152K 0.02% 1139
2016
Q1
$43.1M Buy
1,589,698
+793,138
+100% +$21.2M 0.03% 1100
2015
Q4
$23.1M Buy
796,560
+5,352
+0.7% +$148K 0.01% 1652
2015
Q3
$21.5M Hold
791,208
0.01% 1672
2015
Q2
$21.7M Hold
791,208
0.01% 1776
2015
Q1
$21.1M Sell
791,208
-39,816
-5% -$917K 0.01% 1742
2014
Q4
$17.6M Buy
831,024
+69,172
+9% +$1.55M 0.01% 1877
2014
Q3
$18.1M Hold
761,852
0.01% 1728
2014
Q2
$17.6M Buy
761,852
+83,642
+12% +$1.85M 0.01% 1774
2014
Q1
$15.5M Buy
678,210
+8,940
+1% +$190K 0.01% 1819
2013
Q4
$12.4M Sell
669,270
-23,490
-3% -$409K 0.01% 1998
2013
Q3
$11.7M Buy
692,760
+7,910
+1% +$133K 0.01% 1971
2013
Q2
$10.6M Buy
+684,850
New +$11.4M 0.01% 1935

Other funds holding NVO

Dimensional Fund Advisors's NVO Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Novo Nordisk (NVO) stake by 3.3% in Q2 2026, buying an estimated $1.8M and bringing the position to 1,292,688 shares worth $62M. The position accounts for 0.01% of the portfolio, ranked #1469.

Dimensional Fund Advisors first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $231M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Dimensional Fund Advisors held 1,292,688 shares of Novo Nordisk worth $62M as of Q2 2026.
  • Dimensional Fund Advisors bought 41,840 Novo Nordisk shares in Q2 2026, an estimated $1.8M.
  • Novo Nordisk made up 0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #1469 holding.
  • Dimensional Fund Advisors first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
  • Dimensional Fund Advisors's Novo Nordisk position peaked at $231M in Q2 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.